Register Login

Avalo Therapeutics Inc. (AVTX)

(70% Positive) AVALO THERAPEUTICS, INC. (AVTX) Announces Enrollment Update for expected Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 29, 2025, 11:07 a.m.

    📋 AVALO THERAPEUTICS, INC. (AVTX) - Clinical Trial Update

    Filing Date: 2025-10-29

    Accepted: 2025-10-29 07:04:33

    Event Type: Clinical Trial Update

    Event Details:

    Avalo Therapeutics Inc. (AVTX) Announces Clinical Trial Update Avalo Therapeutics Inc. (AVTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: expected, milestone
    • Diseases/Conditions: immune-mediated inflammatory diseases, our AVTX-009 program
    • Clinical Stage: Phase 2, Phase 2 trial
    • Collaboration: Avalo Therapeutics, Inc.
    • Updated Timeline: October 29, 2025
      • expected in mid-2026

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Avalo Therapeutics Inc.
    • CIK: 0001534120
    • Ticker Symbol: AVTX
    • Period End Date: 2025-10-29
    • Document Type: 8-K

Search

News categories